Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Clin Cancer Res. 2016 Dec 30;23(13):3396–3404. doi: 10.1158/1078-0432.CCR-16-1678

Figure 1.

Figure 1

HIF-1α-specific antibodies can be detected in the sera of breast cancer patients with the highest incidence and levels in those with the triple negative subtype. (A) Incidence of positive HIF-1α-specific antibodies in each group. *p<0.05, **p<0.01, ***p<0.001 compared to the control group. (B) HIF-1α-specific IgG (μg/ml ± SEM) for the experimental groups. ***p<0.001 between groups. TNBC: triple negative breast cancer; ER+: estrogen receptor positive breast cancer; HER2+: human epidermal growth factor receptor 2 positive breast cancer.